Newly Published Research Indicates the Potential of Phenoxodiol to Protect Against Neuropathy
August 13 2007 - 9:41AM
PR Newswire (US)
SYDNEY, Australia and NEW CANAAN, Conn., Aug. 13
/PRNewswire-FirstCall/ -- Results of a study published in the
current issue of BMC Neuroscience show that investigational drug
phenoxodiol, currently being developed as a therapy for late-stage,
chemo-resistant prostate, ovarian and cervical cancers, may also
have the potential to be use used in conjunction with cisplatin
chemotherapy to prevent induction of platinum-induced neuropathy.
The new study examined whether phenoxodiol could protect against
cisplatin-induced neurite inhibition in PC12 cells as an indication
of the potential to protect against neuropathy. In the study, the
effect of phenoxodiol on cisplatin induced neurite toxicity was
assessed by measurement of neurite outgrowth. Study results show
the addition of phenoxodiol showed no cytotoxicity at low doses and
blocked the cisplatin induced neurite toxicity. The study concludes
that successful prophylactic treatment of cisplatin induced
neuropathy with phenoxodiol could allow more intensive and hence
more effective cisplatin therapy. Overall, given the dose and
treatment limiting neuropathic side effects of cisplatin, one of
the most widely used chemotherapeutic drugs, and the lack of any
currently available prophylactic treatment or cure, the study also
concludes that phenoxodiol is a promising candidate that warrants
further testing. "Historical data demonstrates that phenoxodiol has
the ability to overcome drug resistance in cancer cells," said Dr.
Ann Turnley, Associate Director, Centre for Neuroscience,
University of Melbourne. "This study indicates that phenoxodiol has
the potential to protect normal cells from the toxic effects of
chemotherapy and may help in reducing some of the side effects."
The title of the new research article is Phenoxodiol protects
against Cisplatin induced neurite toxicity in a PC-12 cell model --
and may be downloaded at
http://www.biomedcentral.com/1471-2202/8/61. Oral phenoxodiol in
combination with weekly carboplatin is currently being studied in a
multi-national Phase III clinical trial called OVATURE. The OVATURE
trial is taking place in the United States, Europe, and Australia
and is designed to demonstrate the safety and effectiveness of
phenoxodiol in combination with weekly carboplatin compared to
weekly carboplatin alone for the treatment of ovarian cancer that
has become resistant or refractory to platinum therapy. More
information about the OVATURE trial is available at
http://clinicaltrials.gov/ and type in "OVATURE" in the search
option. About phenoxodiol: Phenoxodiol is being developed as a
therapy for late-stage, chemo-resistant prostate, ovarian and
cervical cancers. Phenoxodiol is an investigational drug and, as
such, is not commercially available. It is a novel-acting drug that
inhibits key pro-survival signaling pathways operating via
sphingosine-1-phosphate and Akt. Inhibition of these pathways leads
to prevention of phosphorylation of key anti-apoptotic proteins
such as XIAP. Loss of activity of these proteins restores the
ability of chemoresistant tumor cells to undergo apoptosis in
response to chemotherapy. The putative molecular target for
phenoxodiol is a tumor-specific protein, accounting for the highly
selective nature of the drug. About Marshall Edwards Inc: Marshall
Edwards, Inc. (NASDAQ:MSHL) is a specialist oncology company
focused on the clinical development of novel anti-cancer
therapeutics. These derive from a flavonoid technology platform
which has generated a number of novel compounds characterized by
broad ranging efficacy against a range of cancer targets with few
side effects. The unique combination of efficacy and safety has
been explained by their ability to target an enzyme present on the
surface of cancer cells, thereby inhibiting the production of
pro-survival proteins within the cell. Marshall Edwards, Inc. has
licensed rights from Novogen Limited (NASDAQ:NVGN) to bring three
oncology drugs -- phenoxodiol, NV-196 and NV-143 -- to market
globally. Marshall Edwards, Inc. is majority owned by Novogen, an
Australian biotechnology company that is specializing in the
development of therapeutics based on a flavonoid technology
platform. Novogen, based in Sydney, Australia, is developing a
range of therapeutics across the fields of oncology, cardiovascular
disease and inflammatory diseases. More information on phenoxodiol
and on the Novogen group of companies can be found at
http://www.marshalledwardsinc.com/ and http://www.novogen.com/.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third arty patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements. Contact:
David Sheon 202 518-6321 DATASOURCE: Marshall Edwards, Inc.
CONTACT: David Sheon, for Marshall Edwards, Inc., +1-202-518-6321,
, or Prof Alan Husband of Marshall Edwards, Inc., 011 61 2 9878
0088, Web site: http://www.marshalledwardsinc.com/
http://www.novogen.com/ http://www.biomedcentral.com/1471-2202/8/61
http://clinicaltrials.gov/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024